Effect of Remdesivir in COVID-19 in Terms of Hospital Discharge and Mortality Benefits
DOI:
https://doi.org/10.59058/jaimc.v20i1.12Keywords:
COVID-19, Pandemics, Remdesivir, Treatment Outcome, MortalityAbstract
Background & Objective: There is no first line antiviral treatment for Corona Virus Disease 2019 (Covid-19). Remdesivir is used as antiviral drug for covid 19 in different parts of world with variable results.The objective of our study was to assess the effect of Remdesivir in Covid-19, in terms of time to discharge from hospital and mortality rate benefit.
Methods: An interventional, single-center study conducted at Corona Wards of DHQ University teaching hospital Gujranwala. Two categories were made using simple random sampling technique. First category was marked 'Remdesivir group', to whom after Informed Consent Injection Remdesivir (200 mg on the principal day followed by 100 mg every day for the following four days) was given. Second category was the'Control group'; they were not given the injection Remdesivir. Total 248 patients were selected for the study.
The Remdesivir category included 124 patients and the Control category involved 124 patients. Collected data was analyzed using SPSS 23.0. All baseline characters and variables in history were calculated as Mean and standard deviations for quantitative variables and as percentages for frequencies of qualitative variables. Univariate comparison for binary variables was performed with Chi-Square test. A p-value of <0.05 was considered as significant.
Results: In the Remdesivir category 23 (18.5%) had mild illness, 50 (40.3%) had moderate illness and 51 (41.2%) patients had severe illness. In the Control category 26 (20.9%) had mild illness, and 50 (40.3%) had moderate illness and 48(38.8%) patients had severe illness. The median hospital stay days in Remdesivir category was 13 (95% CI: 12 - 15) and total death rate was 36.44%. The median hospital stay days in Control category was 11 (95% CI: 10 - 12) and the death rate was 31.35%. p- value .40.
Conclusion: The information showed that Remdesivir was not better than the standard of care treatment in shortening the hospital stay days in patients with proven Covid-19. No Mortality benefit was seen with Remdesivir treatment.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 JAIMC: Official Journal Of Allama Iqbal Medical College
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
